Hair Loss on GLP-1s (2026 Data): Temporary, Scary, Normal

Tip: This is a sign of SUCCESS

Hair loss occurs because your body is losing weight faster than it's "comfortable" with.
It's temporary. It grows back.
Don't stop your medication over this alone.

What's Happening (The Science)

Telogen effluvium = temporary hair shedding triggered by rapid weight loss, illness, or stress.

The timeline:

Trigger: Rapid weight loss begins
Delay phase: 2-3 months (hair stays in scalp, looks normal)
Shedding phase: 3-6 months in (hair falls out in clumps)
Recovery phase: 6-9 months (new hair visible, continues growth)

Why this happens:

Your body allocates energy to weight loss, hair becomes "non-essential"
~50% of hair follicles simultaneously shift from growth phase to rest
Rest phase ends → hair falls out → new cycle begins

The Reality Check

Who experiences this:

~70-80% of people losing 10+ pounds/month
More common with aggressive GLP-1 doses (higher tirzepatide, semaglutide)
Affects all hair types (curly, straight, textured)

How bad it gets:

Mild: Extra hair in drain, hairbrush has more than normal
Moderate: More hair than usual for 2-3 weeks
Severe: Noticeable thinning, bald-ish spots (extremely rare in most cases)

Recovery timeline:

Starts improving: 6-9 months after you stabilize weight
Full recovery: 12-18 months from initial trigger
Hair grows back SAME as it was before (thicker if you gained weight previously, etc.)

What the Latest Research Says (2025-2026)

Several major reviews published in 2025-2026 have clarified the link between GLP-1s and hair loss:

Which drugs carry the most risk:

A systematic review of 24 studies found semaglutide and tirzepatide have the highest reported incidence of hair loss among GLP-1s.
Semaglutide-associated hair loss appears dose-dependent — doses under 2 mg weekly (diabetes doses) are rarely implicated, while higher obesity-treatment doses (1.7 mg, 2.4 mg) are more commonly linked.
Tirzepatide, which produces the greatest average weight loss, was most frequently linked to telogen effluvium specifically.
No significant signal was found for liraglutide, dulaglutide, exenatide, or lixisenatide.

FAERS data (2016-2025):

A 10-year analysis of the FDA Adverse Event Reporting System detected alopecia signals for semaglutide in 2022 and 2024, and for tirzepatide in 2024 and 2025.
The 2025 tirzepatide signal was the highest magnitude finding in the entire dataset (reporting odds ratio 2.08).
Dechallenge data (improvement after stopping) was documented in 50-63% of cases, suggesting the hair loss is reversible when the drug is withdrawn.
Women are disproportionately affected across all GLP-1 classes.

What this means for you: The research confirms what clinicians have observed — hair loss is a known side effect driven primarily by rapid weight loss, not a direct toxic effect of the drug. It remains temporary and reversible in nearly all cases.

Foundayo (Orforglipron) — The First Oral GLP-1

Foundayo (orforglipron) was FDA-approved in April 2026 as the first oral small-molecule GLP-1 receptor agonist for weight management. Clinical trial data from the ATTAIN-1 and ATTAIN-2 Phase 3 studies shows:

Hair loss incidence: 4-5% of participants across orforglipron doses versus 2% on placebo.
By gender: 7.0% of women vs 0.9% of men on orforglipron reported hair loss (compared to 3.0% vs 0.7% on placebo).
Hair loss is now listed as a common adverse reaction (≥5%) in the prescribing information.
As with injectable GLP-1s, orforglipron-associated hair loss was linked to weight reduction.

The takeaway: Even the new oral GLP-1s show the same pattern — hair loss is a class effect driven by weight loss, not unique to any specific drug or injection method. Switching from an injectable to an oral GLP-1 is unlikely to prevent it.

Ongoing Uncertainty

Not all research agrees. A 2025 retrospective cohort study in the Journal of the American Academy of Dermatology noted conflicting evidence — some theories suggest GLP-1s may improve hair health through better insulin sensitivity and scalp blood flow. The current consensus is that rapid weight loss is the primary driver, but more prospective trials are needed.

What You CAN Do (Minimize + Support)

Note: Nothing stops it completely

The best you can do is minimize severity + speed up recovery.
Hair loss from weight loss is largely physiological, not fixable with supplements alone.

Nutrition Support

Protein (non-negotiable):

Minimum: 100g protein/day while losing
Hair = keratin = made of protein
Not enough protein = worse shedding — see our protein deficit guide

Specific nutrients:

Biotin: 2.5-5mg daily (biotin supplement) (found in eggs, nuts, salmon)
Iron: Especially important for women (menstruation + weight loss = deficiency risk)
Vitamin D: Many people are deficient; affects hair health
Zinc: Supports hair growth

Foods to eat:

Eggs (biotin protein bomb)
Salmon (omega-3s reduce inflammation)
Spinach (iron, vitamin C)
Nuts/seeds (biotin, zinc)
Bone broth (collagen protein)

What NOT To Do

Don't Do This	Why
Stop GLP-1 medication	Hair sheds anyway from weight loss you ALREADY did
Start aggressive supplements	Expensive, limited evidence, risk of interactions
Panic	Stress makes it worse (cortisol affects hair)
Expect instant fixes	Hair grows ~1/2 inch/month, minimum 6-month timeline